INS and type 2 diabetes mellitus: People with type 2 diabetes (T2D) may progress to requiring both basal and bolus (prandial) insulin therapy to attain glycemic control, thus necessitating multiple daily insulin injections (MDIs).1,2 However, glycated hemoglobin (HbA1c) targets are often not reached with MDI therapy.3–5 Moreover, results of surveys and other real-world studies indicate that nonadherence to insulin therapy is common, especially with more prescribed injections and as regimens become more complex.6–9 Indeed, taking more daily injections is an independent risk factor for nonadherence.6